- Annual Worldwide Sales of Synagis(R) Exceed $1 Billion for First Time - Major Milestones Achieved in 2005 * $1.2 billion in 2005 total revenues, increasing nine percent over 2004 * RSV franchise strengthened and expanded - Worldwide Sales of Synagis grew 13 percent to $1.1 billion in 2005 - U.S. co-promotion and international distribution agreements for Synagis restructured providing substantial strategic, operational and financial benefits - Completed enrollment in two late-stage studies with Numax(TM) - Converted to liquid formulation of Synagis in U.S. - Began clinical testing with combination vaccine against RSV and PIV-3 - In-licensed rights to anti-RSV small molecule compounds * Substantial progress achieved with influenza vaccine franchise - Pivotal Phase 3 trial results showed refrigerator-stable formulation of FluMist(R), CAIV-T, was 55 percent More effective than flu shot - sBLA for CAIV-T submitted to FDA for approval for use in healthy 5-49 year olds - State-of-the-art influenza vaccine Manufacturing facility approved by FDA - Patent estate expanded for using reverse genetics in influenza vaccine production - Entered into a research agreement with NIH to develop pandemic influenza vaccines * 11 new targets added to R&D portfolio * Three Investigational New Drug applications filed * HPV vaccine license - More available
|
| ||
| No Ebay Marketplace Listings Found | ||
More results for
Ethyol on Google
Google is currently the number one search engine on the net. If you want to find anything on
the web related to Ethyol then Google is a great place to start.
More results for Ethyol on Overture
Overture is the largest partner search engine on the web. If you are
interesting in buying a product related to Ethyol or obtaining services related to Ethyol then
Overture is the place to start.
Try Asking about
Ethyol
Ask.com may produce some results for Ethyol that you can not find anywhere else. Ask
will also show you more searches related to Ethyol and provide an automatic picture search for
Ethyol